Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Understanding schizophrenia and diabetes.

Ted Dinan1, Robert Peveler, Richard Holt

  • 1University College Cork, National University of Ireland.

Hospital Medicine (London, England : 1998)
|August 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harmful anachronism: World Athletics reinstates gene testing to participate in women's competitions.

British journal of sports medicine·2026
Same author

Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss.

Advances in therapy·2025
Same author

GJA8-associated developmental eye disorders: a new multicentre study highlights mutational hotspots and genotype-phenotype correlations.

European journal of human genetics : EJHG·2025
Same author

Deletion upstream of MAB21L2 highlights the importance of evolutionarily conserved non-coding sequences for eye development.

Nature communications·2024
Same author

Clinical and functional heterogeneity associated with the disruption of retinoic acid receptor beta.

Genetics in medicine : official journal of the American College of Medical Genetics·2023
Same author

Individuals with heterozygous variants in the Wnt-signalling pathway gene <i>FZD5</i> delineate a phenotype characterized by isolated coloboma and variable expressivity.

Ophthalmic genetics·2023

Severe mental illness, particularly schizophrenia, significantly increases type 2 diabetes risk. Individuals with schizophrenia face a 2-4x higher risk, with 15-18% prevalence, highlighting an overlooked public health concern.

Area of Science:

  • Endocrinology
  • Psychiatry
  • Public Health

Background:

  • Type 2 diabetes is a growing global health issue.
  • Severe mental illness (SMI) is an underrecognized risk factor for type 2 diabetes.
  • Schizophrenia is associated with substantial metabolic complications.

Purpose of the Study:

  • To highlight the elevated risk of type 2 diabetes in individuals with schizophrenia.
  • To underscore the importance of understanding the link between severe mental illness and diabetes.
  • To emphasize the need for integrated care approaches.

Main Methods:

  • Literature review on diabetes prevalence in schizophrenia.
  • Analysis of epidemiological data comparing diabetes risk in schizophrenia patients versus the general population.

Related Experiment Videos

  • Synthesis of current understanding of risk factors.

    • Main Results:

    • Individuals with schizophrenia exhibit a 2 to 4 times greater risk of developing diabetes compared to the general population.
    • The prevalence of type 2 diabetes within the schizophrenia population ranges from 15% to 18%.
    • This increased risk associated with schizophrenia is often overlooked in clinical practice and research.

    Conclusions:

    • Severe mental illness, specifically schizophrenia, represents a significant and often overlooked risk factor for type 2 diabetes.
    • Integrated healthcare strategies are crucial for managing diabetes risk in individuals with schizophrenia.
    • Further research is warranted to elucidate the mechanisms underlying this association and to develop targeted interventions.